We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) in 2024, we have been developing a range of biosensor devices and related services, beginning with a continuous glucose monitoring (“CGM”) product.
Stage not disclosed · ActiveModality: biosensor device
Indications
continuous glucose monitoring (diabetes)(Stage not disclosed)
Catalysts
— 2026
Status note Next-generation continuous glucose monitoring biosensor platform acquired from Waveform (January 2024). Advancing through final design stages; pivotal clinical trials planned for 2026.
PrePsia
Stage not disclosed · ActiveModality: in vitro diagnostic (biomarker)
Indications
preeclampsia risk assessment(Stage not disclosed)
Status note Preeclampsia-risk assessment technology acquired via Metabolomics Diagnostics Ltd. (September 2024). 2025 activities directed toward continued development, validation and regulatory preparation.
EpiCapture
Stage not disclosed · ActiveModality: in vitro diagnostic (molecular)
Indications
prostate cancer (prognostic, progression to aggressive disease)(Stage not disclosed)
Status note Non-invasive urine-based prognostic test for progression to aggressive prostate cancer, acquired October 2024. Two clinical studies planned to strengthen clinical claims; being prepared for submission to the New York State Department of Health as a laboratory-developed test.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.